Health
International Clinical Trial Results Released! Responding to the Virus Resurgence, Lianhua Qingwen Capsules Provide New Evidence
SINGAPORE, Dec. 21, 2023 /PRNewswire/ -- Recently, according to multiple reports from local Singaporean media, confirmed cases of COVID-19 are steadily increasing, with the average number of daily hospitalizations on the rise. The virus, once vigorously fought against, seems to be making a comeba...
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
* The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. * The deal enables Servier to potentially bring additional indications and accessibility of TIBSOVO® to patients in Greater China (including main...
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed rele...
EVERISE ANNOUNCES SUCCESSFUL CLOSURE OF INVESTMENT BY WARBURG PINCUS, JOINING BROOKFIELD FOR THE NEXT PHASE OF GROWTH
NEW YORK, SINGAPORE and MUMBAI, Dec. 21, 2023 /PRNewswire/ -- Everise, a leading global healthcare services outsourcing company, announced today the successful completion of the company's previously announced investment from Warburg Pincus. Warburg Pincus joins existing investorBrookfield, valuin...
ENA Building Momentum Globally in Support of Emergency Nurses
Partnerships help gold standard TNCC and ENPC courses reach more international ED nurses SCHAUMBURG, Ill., Dec. 21, 2023 /PRNewswire/ -- After a year dedicated to expanding its international connections, theEmergency Nurses Association stands poised to reach more emergency nurses globally with k...
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial
WUXI, China, Dec. 20, 2023 /PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) inCh...
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
GAITHERSBURG, Md., Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
/DISREGARD RELEASE: YS Biopharma/
We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting onDecember 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained err...
CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors
HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital inChina. "A single center, single-arm, dose-escalation, exploratory clinical trial to examine t...
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
PROVIDENCE, R.I., Dec. 21, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologic...
Genevoyager Unveils Gene Therapy CDMO Facility in Milestone Move
PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider of one-stop CRO/CDMO services for gene therapy products, proudly announces the official opening of its Contract Development and Manufacturing Organization (CDMO) facility. This significant ...
Dx&Vx co-develops a bio-healthcare big data platform with LG CNS
- Possessing human genome and microbiome data in all clinical stages - Becoming a global bio-healthcare big data platform company SEOUL, South Korea, Dec. 20, 2023 /PRNewswire/ -- Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS. Dx&Vx recently anno...
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...
Fapon Shines at JITMM 2023
DONGGUAN, China, Dec. 20, 2023 /PRNewswire/ -- Fapon, a global leading life sciences company, showcased its expertise at the Joint International Tropical Medicine Meeting (JITMM) 2023, the leading tropical-medicine conference in Southeast Asia held in Bangkok, Thailand, from December 12th to 15th....
INNOTIER TEAMED UP WITH TERESA MO & JENNIFER YU TO LAUNCH A NEW FASHIONABLE COLLECTION FOR EPIDEMIC PREVENTION
HONG KONG, Dec. 20, 2023 /PRNewswire/ -- This winter is the first winter in Hong Kong after the lifting of the mask mandate. The Department of Health expects a high chance of outbreaks of upper respiratory tract diseases, mainly seasonal influenza.Hong Kong has already experienced a summer flu ou...
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Updates Resources for Sixth Year
Collective effort to optimize and standardize treatment practices now covers more than 90% of adult cancer incidences plus an increasing number of pediatric diseases. PLYMOUTH MEETING, Pa., Dec. 20, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading ac...
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload pl...
Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis (RA) in a Phase Ⅲ clinical trial...
ShiraTronics Announces Landmark Achievement: World's First Implant of its Innovative Chronic Migraine System
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- ShiraTronics, Inc., a trailblazing clinical-stage medical device company, today announced a landmark achievement with the successful implantation of its Chronic Migraine System in the world's first six patients. This remarkable milestone represents a sig...
Parexel Recognized with Frost & Sullivan's 2023 North American Customer Value Leadership Award for Impactful Real-world Evidence Solutions Addressing Customer Needs
Informing clinical development, enhancing the patient experience, mitigating risk and meeting health authority requirements across the product lifecycle are the foundation of Parexel's Real-world Evidence solutions SAN ANTONIO, Texas, Dec. 19, 2023 /PRNewswire/ -- Frost & Sullivan today recogniz...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 287 media titles]
2024-04-30 10:11INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00